




This guide was created to help people with previously treated locally advanced or metastatic **ROS1+** non-small cell lung cancer (NSCLC) have more informed conversations with their doctors about JIDEYTRO (pronounced: jih-DAY-troh).

 Review the questions included in this guide to help decide what to ask at your next appointment. Use the space provided on **page 3** to write any additional questions of your own

## **Prepare for your appointment**

- Track your symptoms leading up to your appointment so you can accurately and fully describe them to your doctor
- Write down all your questions and concerns so you can remember them at the doctor's office
- Consider inviting a loved one or friend to come with you to provide support, ask additional questions, or take notes

### **Define your treatment goals**

Treatment goals are personal and may include priorities involving how well the treatment may work for you, the types of possible side effects, and the impact to your daily routine (including work, hobbies, or caring for others). **Complete the sentence below to reflect your treatment goals.**

**My goals for treatment are:**

---



---



---

### **Ask your doctor:**

- How can we make a treatment plan with these goals and priorities in mind?
- Having already received prior ROS1-targeted treatment for NSCLC, what can I expect from this next therapy?

ROS1+=ROS proto-oncogene 1-positive.

## **What is JIDEYTRO™ (zidesamtinib)?**

JIDEYTRO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:

- has spread within the chest or other parts of the body and is caused by an abnormal ROS1 gene, and
- who have received a ROS1 kinase inhibitor.

It is not known if JIDEYTRO is safe and effective in children.

## **IMPORTANT SAFETY INFORMATION**

**JIDEYTRO can cause serious side effects, including:**

- **Central nervous system (CNS) effects.** Tell your healthcare provider right away if you or your family member taking JIDEYTRO develop any new or worsening CNS symptoms during treatment, including:
  - dizziness
  - walking, balance, or coordination problems
  - fainting

CNS effects continued on the next page.

**Please see full Important Safety Information on pages 5–7 and full Prescribing Information and Patient Information for JIDEYTRO.**

 *The following questions can help you and your doctor decide if JIDEYTRO should be your next ROS1+ NSCLC treatment*

**Jideytro**<sup>TM</sup>  
(zidesamtinib) | 25 mg  
100 mg tablets



## Considering JIDEYTRO

- Could JIDEYTRO be an appropriate treatment option for me?
- How do my cancer and treatment history compare with those of people in the JIDEYTRO clinical study?
  - **When you ask this:** Consider mentioning specifics such as brain metastases, resistance mutations, and number of previous ROS1-targeted treatments



## What to expect with JIDEYTRO

- Can you tell me the potential benefits and possible side effects of JIDEYTRO?
- Can JIDEYTRO work against resistance mutations?
- Can JIDEYTRO work against brain metastases?
- For how long did people see results with JIDEYTRO, and how will we know if it's working?



## Taking JIDEYTRO and the treatment experience

- What is the dosing for JIDEYTRO (how many pills would I take, and how often would I take them)?
- Is there anything I should or shouldn't do while taking JIDEYTRO, like certain activities or taking other medications?
- Did people experience side effects that required them to stop treatment or reduce their dose?
- Based on what has been seen with JIDEYTRO, how might treatment change my daily routine?



## Additional support

- Can you recommend any resources to support my emotional and mental well-being?
- Where can I go if I need help paying for treatment or financial counseling?

NSCLC=non-small cell lung cancer.

## IMPORTANT SAFETY INFORMATION (cont.)

**JIDEYTRO can cause serious side effects, including:** (cont.)

- **Central nervous system (CNS) effects.** Tell your healthcare provider right away if you or your family member taking JIDEYTRO develop any new or worsening CNS symptoms during treatment, including: (cont.)
  - forgetfulness, confusion, attention or thinking problems
  - mood or personality changes, including anxiety, irritability
  - speaking problems
  - depression, including thoughts of suicide or dying
  - seizures
  - seeing or hearing things that are not real (hallucinations)

Please see full Important Safety Information on [pages 5–7](#) and full [Prescribing Information](#) and [Patient Information](#) for JIDEYTRO.



## For care partners

The care partner of a person with cancer is a vital source of support. If you're a care partner for someone with *ROS1*+ NSCLC, you can help by advocating for them during medical visits and ensuring their voice is heard. You can also assist by taking notes, doing research, and making sure that conversations with the care team cover all of your loved one's concerns.

### Care partners should also feel welcome to ask questions during doctor visits, such as:

- How can I help ensure a smoother treatment experience for my loved one?
- What should we be looking out for when it comes to cancer symptoms or medication side effects?

### Organize your thoughts

Use this space to write **additional questions** and **anything you want to remember** for discussion with your doctor:

---

---

---

---

---

---

---

Use this space to track **symptom details** leading up to your doctor's appointment:

---

---

---

---

---

---

---

## IMPORTANT SAFETY INFORMATION (cont.)

**JIDEYTRO can cause serious side effects, including:** (cont.)

- **Changes in the electrical activity of your heart called QT prolongation.** QT prolongation can cause irregular heartbeats that can be life-threatening or cause sudden death. Your healthcare provider will do tests before and during your treatment with JIDEYTRO to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with JIDEYTRO.

Please see full Important Safety Information on [pages 5–7](#) and full [Prescribing Information](#) and [Patient Information](#) for JIDEYTRO.

## **More resources**

Read about treatment with JIDEYTRO at [JIDEYTRO.com](https://JIDEYTRO.com), and learn about Nuvalent Patient Support programs by visiting [NuvalentPatientSupport.com](https://NuvalentPatientSupport.com). You can also explore support for people with ROS1+ NSCLC through these patient advocacy organizations:



These organizations are separate from Nuvalent and are not connected to JIDEYTRO. They are listed to provide extra information and support, and they should not replace medical advice from your care team.



Scan the QR code or visit [JIDEYTRO.com](https://JIDEYTRO.com) for more resources

## **IMPORTANT SAFETY INFORMATION (cont.)**

### **JIDEYTRO can cause serious side effects, including: (cont.)**

- **Lung problems.** JIDEYTRO can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough (with or without mucus), or fever.
- **Bone fractures.** JIDEYTRO can increase your risk of bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.

Please see full Important Safety Information on [pages 5–7](#)  
and full [Prescribing Information](#) and [Patient Information](#) for JIDEYTRO.

## What is JIDEYTRO™ (zidesamtinib)?

JIDEYTRO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:


- has spread within the chest or other parts of the body and is caused by an abnormal ROS1 gene, and
- who have received a ROS1 kinase inhibitor.

It is not known if JIDEYTRO is safe and effective in children.

**Jideytro**<sup>TM</sup>  
(zidesamtinib) | 25 mg  
100 mg tablets

## IMPORTANT SAFETY INFORMATION

**JIDEYTRO can cause serious side effects, including:**




**Central nervous system (CNS) effects.** Tell your healthcare provider right away if you or your family member taking JIDEYTRO develop any new or worsening CNS symptoms during treatment, including:


- dizziness
- fainting
- walking, balance, or coordination problems
- forgetfulness, confusion, attention or thinking problems
- speaking problems
- seizures
- mood or personality changes, including anxiety, irritability
- depression, including thoughts of suicide or dying
- seeing or hearing things that are not real (hallucinations)



**Changes in the electrical activity of your heart called QT prolongation.** QT prolongation can cause irregular heartbeats that can be life-threatening or cause sudden death. Your healthcare provider will do tests before and during your treatment with JIDEYTRO to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with JIDEYTRO.



**Lung problems.** JIDEYTRO can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough (with or without mucus), or fever.




**Bone fractures.** JIDEYTRO can increase your risk of bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.

## IMPORTANT SAFETY INFORMATION (cont.)

**JIDEYTRO can cause serious side effects, including:** (cont.)

**Jideytro**<sup>TM</sup>  
(zidesamtinib) | 25 mg  
100 mg tablets



**Muscle pain, tenderness, and weakness (myalgia).** JIDEYTRO can cause myalgia with an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your CPK blood levels every 2 weeks during the first month, then every 1 to 2 months and as needed if you get unexplained muscle pain, tenderness, or weakness during your treatment with JIDEYTRO. Tell your healthcare provider if you develop any of these symptoms.



**Inflammation of the pancreas (pancreatitis).** JIDEYTRO may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider will do blood tests to check your pancreatic enzyme blood levels during treatment with JIDEYTRO. Tell your healthcare provider right away if you get any signs and symptoms of pancreatitis, including upper stomach (abdominal) pain that may spread to the back and get worse with eating, weight loss, or nausea.

**Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you:**

- have nervous system (neurological) or psychiatric problems.
- have heart problems, including a condition called long QT syndrome.
- have lung or breathing problems other than lung cancer.
- are pregnant or plan to become pregnant. JIDEYTRO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JIDEYTRO.

**Females who are able to become pregnant:** Your healthcare provider will do a pregnancy test before you start treatment with JIDEYTRO. Use effective birth control (contraception) during treatment and for 6 months after the last dose of JIDEYTRO. Talk to your healthcare provider about birth control methods that may be right for you.

**Males with a female partner who are able to become pregnant:** Use effective birth control during treatment and for 3 months after the last dose of JIDEYTRO.

- are breastfeeding or plan to breastfeed. It is not known if JIDEYTRO passes into your breast milk. **Do not** breastfeed during treatment and for 1 week after your last dose of JIDEYTRO. Talk to your healthcare provider about the best way to feed your baby during treatment with JIDEYTRO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking JIDEYTRO with certain other medicines may affect the amount of JIDEYTRO or other medicines in your blood and may cause side effects or affect the way that JIDEYTRO or other medicines work.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Please see full [Prescribing information](#) and [Patient Information](#) for JIDEYTRO.

## IMPORTANT SAFETY INFORMATION (cont.)



### What should I avoid while taking JIDEYTRO?

- Do not drive or operate heavy machinery during treatment if you develop side effects that can impact your mental alertness or coordination.

### What are the most common side effects of JIDEYTRO?

The most common side effects of JIDEYTRO include:

- swelling (edema)
- tiredness
- numbness or tingling in your arms or legs
- shortness of breath
- constipation

The most common severe abnormal blood test results include increased creatine phosphokinase (CPK), increased triglycerides, decreased white blood cell counts and decreased red blood cell counts.

JIDEYTRO may cause fertility problems in males and females. Talk to your healthcare provider if fertility is a concern for you.

These are not all the possible side effects of JIDEYTRO. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call **1-800-FDA-1088**.

**Please see full [Prescribing information](#) and [Patient Information](#) for JIDEYTRO.**



Nuvalent and the associated logo are registered trademarks of Nuvalent, Inc., and JIDEYTRO, Nuvalent Patient Support, and the associated logos are trademarks of Nuvalent, Inc.

© 2026 Nuvalent. All rights reserved. ZID-US-0014v1.0 07/2026